🇺🇸 ClinicalTrials.govClinicalTrials.gov · 试验状态变更Doubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·源无时间·以抓取为准·⟳ 抓取 20:05:01·⚡ 决策 10-15 20:08:19 +3m18s·12.4 天前
ClinicalTrials.gov 登记一项 ENTYVIO 老年感染风险 Medicare 数据库回顾性观察研究，无结果读出、无基本面增量
这是一项回顾性 Medicare 数据库观察研究的登记/状态变更，不产生任何新的疗效或安全性数据、监管决定、标签变更或商业信号；观察性研究登记本身不改变任何上市公司的基本面或短期预期，缺乏可交易方向与正期望 edge。
📄 原文ClinicalTrials.gov · 试验状态变更↗ 原文
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (…
不做 Takeda Pharmaceutical（武田药品）（4502.JP）
NCT07250815 仅为回顾性 Medicare 数据库观察研究的登记/状态更新，无疗效/安全性结果、无监管或标签动作、无销售增量，不构成可交易催化，无 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
NCT07250815 只是一项用 2016–2025 既有 Medicare 数据、比较 ENTYVIO 与 TNF-α 抑制剂/ustekinumab 老年感染率的回顾性观察研究登记，无结果读出、无监管/标签/销售含义，属纯流程性注册信息，不构成交易催化，AVOID。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
主要风险
- 若未来该研究读出提示 ENTYVIO 老年感染风险显著高于/低于对照，才可能成为武田或竞品的安全标签催化，但那是独立的未来事件，本次登记不包含该信息
先例如何影响了这次决策
对本次决策的影响:未改变结论：无催化、无方向，直接 AVOID
方向:无可引用先例；回顾性观察研究的单纯登记在机制上不含价格相关信息，无需先例即可判定无 edge
涨幅量级:不存在可校准的反应幅度（无基本面增量）
形态:无
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`entyvio vedolizumab vs tnf inhibitor ustekinumab infection elderly database study | nct07250815 entyvio medicare infections older uc crohn observational study`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此
原文全文
展开原文 · 837 字
More older people (more than 65 years of age) around the world are getting Ulcerative Colitis (UC) or Crohn's Disease (CD). This is happening because people are living longer and because more people overall are developing UC or CD. Medicines that treat UC/CD, however, might make it easier for older adults to get infections.
The main aim of this study is to learn if there is a difference in the number and type of infections in older people when treated with either ENTYVIO or other advance medicines (TNF-alpha inhibitors or ustekinumab) that reduce swelling and pain by blocking a chemical in the body (called TNF-alpha).
The study will include people aged 65 years and older UC or CD who used either ENTYVIO with ustekinumab or a TNF-alpha inhibitor between 2016 and 2025.
Data will be collected from existing Medicare databases.
The main aim of this study is to learn if there is a difference in the number and type of infections in older people when treated with either ENTYVIO or other advance medicines (TNF-alpha inhibitors or ustekinumab) that reduce swelling and pain by blocking a chemical in the body (called TNF-alpha).
The study will include people aged 65 years and older UC or CD who used either ENTYVIO with ustekinumab or a TNF-alpha inhibitor between 2016 and 2025.
Data will be collected from existing Medicare databases.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2b7859942e· 2026-10-15 20:08 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前